ECSP088411A - USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES. - Google Patents
USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES.Info
- Publication number
- ECSP088411A ECSP088411A EC2008008411A ECSP088411A ECSP088411A EC SP088411 A ECSP088411 A EC SP088411A EC 2008008411 A EC2008008411 A EC 2008008411A EC SP088411 A ECSP088411 A EC SP088411A EC SP088411 A ECSP088411 A EC SP088411A
- Authority
- EC
- Ecuador
- Prior art keywords
- sdf
- prevention
- treatment
- neurological diseases
- neurological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere al uso de SDF-1, o de un agonista de actividad de SDF-1, para el tratamiento y/o prevención de una enfermedad neurológica.The invention relates to the use of SDF-1, or an agonist of SDF-1 activity, for the treatment and / or prevention of a neurological disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05110206 | 2005-10-31 | ||
US73414205P | 2005-11-07 | 2005-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088411A true ECSP088411A (en) | 2008-05-30 |
Family
ID=38006228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008411A ECSP088411A (en) | 2005-10-31 | 2008-04-29 | USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES. |
Country Status (2)
Country | Link |
---|---|
EC (1) | ECSP088411A (en) |
IL (1) | IL190842A0 (en) |
-
2008
- 2008-04-14 IL IL190842A patent/IL190842A0/en unknown
- 2008-04-29 EC EC2008008411A patent/ECSP088411A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL190842A0 (en) | 2008-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058173A1 (en) | USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES | |
CL2016002589A1 (en) | Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348). | |
UY29899A1 (en) | USE OF FLIBANSERINE FOR THE TREATMENT OF PREMENOPAUSIC SEXUAL DESIRE DISORDERS | |
CR10730A (en) | ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE | |
PA8637301A1 (en) | DERIVATIVES OF AMINO-5, 5-DIFENYLIMIDAZOLONE FOR THE INHIBITION OF THE B-SECRETASE | |
PA8772101A1 (en) | IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED | |
CL2007002017A1 (en) | COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE. | |
MX2007010560A (en) | Roflumilast for the treatment of diabetes mellitus. | |
EA200702529A1 (en) | FUNGICIDAL COMBINATION OF BIOLOGICALLY ACTIVE SUBSTANCES | |
ITRM20050446A1 (en) | USE OF HYDROXYLATED AND GLUCOSIDATED STYLBENES FOR THE PREVENTION AND TREATMENT OF EYE PATHOLOGIES. | |
AR057643A1 (en) | LACOSAMIDE FOR ATTACHED THERAPY | |
WO2007013666A3 (en) | Anti-tumor agents comprising r-spondins | |
CL2007000595A1 (en) | Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others. | |
GT200600077A (en) | IMIDAZOLS REPLACED WITH HETEROCICLILAMIDE | |
HN2005030779A (en) | NONADEPSIPEPTIDES ACILATED II | |
DOP2006000024A (en) | THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT | |
UY28313A1 (en) | NONADEPSIPEPTIDOS ACILADOS | |
EA200501528A1 (en) | APPLICATION OF CLUSTERIN FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL NEUROLOGICAL DISEASES | |
PA8806501A1 (en) | TRIAZOLOTRIAZINAS AND TRIAZOLOPIRAZINAS AND ITS USE | |
DK1713438T3 (en) | Medical soap | |
HN2003000104A (en) | CYCLOPENTENE DERIVATIVES | |
AR064214A1 (en) | USE OF EPOTILONES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES | |
ECSP088411A (en) | USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES. | |
BRPI0510503A (en) | compounds and compositions as cathepsin inhibitors | |
NO20072048L (en) | Use of IL-17F for the treatment and / or prevention of neurological diseases. |